Cabergoline or Quinagolide versus Bromocriptine for Hyperprolactinemia with or without Prolactinoma: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Details

Files

Project Line:

Reference List

Project Sub Line:

Reference List

Project Number:

RA1068-000

Question

What is the clinical effectiveness of cabergoline versus bromocriptine as a first-line medication therapy for patients with hyperprolactinemia with or without prolactinoma?
What is the cost-effectiveness of cabergoline versus bromocriptine as a first-line medication therapy for patients with hyperprolactinemia with or without prolactinoma?
What is the clinical effectiveness of quinagolide versus bromocriptine as a first-line medication therapy for patients with hyperprolactinemia with or without prolactinoma?
What is the cost-effectiveness of quinagolide versus bromocriptine as a first-line medication therapy for patients with hyperprolactinemia with or without prolactinoma?
What are the evidence-based guidelines regarding medication therapy for patients with hyperprolactinemia with or without prolactinoma?

Key Message

Four systematic reviews (three with meta-analyses), one randomized controlled trial, and five non-randomized studies were identified regarding the clinical effectiveness of cabergoline versus bromocriptine as a first-line medication therapy for patients with hyperprolactinemia with or without prolactinoma. One evidence-based guideline was identified regarding medication therapy for patients with hyperprolactinemia.

Files

Cabergoline or Quinagolide versus Bromocriptine for Hyperprolactinemia with or without Prolactinoma: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Rapid Response September 18, 2019 View PDF

Last Updated : September 18, 2019